Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | ELOC | Q15369 | 1/20 | 0.33 |
| ▸ | ELOB | Q15370 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31168244 | 0.71 | NOTUM (0.38) | HSD17B3KMT2AKDM4EALDH1A1 | |
| SCHEMBL4538011 | 0.71 | NOTUM (0.38) | HSD17B3KMT2AKDM4EALDH1A1 | |
| SCHEMBL8868709 | 0.67 | MAPT (0.42) | HSD17B3CYP1A2CYP2C19MAPTKMT2A | |
| SCHEMBL13111741 | 0.61 | LMNA (0.48) | HSD17B3MAPTKMT2ALMNAALDH1A1 | |
| SCHEMBL31552864 | 0.61 | HSD17B3 (0.34) | HSD17B3CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL11369450 | 0.58 | HSD17B3 (0.34) | HSD17B3CYP1A2CYP2C19MAPTKMT2A | |
| SCHEMBL17356870 | 0.58 | CYP1A2 (0.45) | CYP1A2CYP2C19MAPTKMT2AMEN1 | |
| SCHEMBL8471378 | 0.57 | AHR (0.37) | MAPTKMT2AMEN1VHLELOC | |
| SCHEMBL9508955 | 0.57 | BCHE (0.48) | LMNAVHLELOCELOBALDH1A1 | |
| SCHEMBL4929830 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011150181-A2 | COMPOSITIONS AND METHODS FOR TREATING OR INHIBITING INFECTION BY FRANCISELLA TULARENSIS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110135689-A1 | Vaccine, therapeutic composition and methods for treating or inhibiting francisella tularenis | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135689-A1 | Vaccine, therapeutic composition and methods for treating or inhibiting francisella tularenis | STING1, IFNG, FPR2 | HSD17B3 2093/4885CYP1A2 4471/4885CYP2C9 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.